Human Microbiome Therapeutics Market Size Worth USD 7.89 Billion by 2034 | CAGR: 22.80%

The human microbiome therapeutics market size is expected to reach USD 7.89 billion by 2034, according to a new study by Polaris Market Research. The report “Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report By Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs), By Therapeutic Area, By Indication, By Approach, By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Human microbiome therapeutics refers to a class of medical treatments designed to target, restore, or modify the composition and activity of the human microbiome, the diverse community of microorganisms, including bacteria, viruses, fungi, and archaea, that live in and on the human body. These therapeutics aim to harness the beneficial properties of the microbiome to prevent, treat, or manage various diseases. They may involve the use of live biotherapeutic products, microbial consortia, genetically engineered microbes, prebiotics, or postbiotics. The usage of human microbiome therapeutics spans multiple therapeutic areas. In gastroenterology, they are used to treat conditions such as Clostridioides difficile infections, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). In oncology, they can enhance responses to immunotherapy by modulating gut bacteria that influence immune function.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market/request-for-sample

They are being explored for metabolic disorders such as obesity and type 2 diabetes, neurological conditions like autism spectrum disorder and Parkinson’s disease, and skin disorders including eczema and acne. Additionally, microbiome-based interventions are being investigated for allergy prevention and women’s health issues, such as bacterial vaginosis. These therapeutics can be administered through oral capsules, dietary supplements, fecal microbiota transplantation (FMT), or topical formulations. The field is rapidly evolving due to advances in microbiome sequencing, synthetic biology, and personalized medicine.

Top of FormHuman Microbiome Therapeutics Market Report Highlights

• In terms of product, the probiotics segment accounted for a major revenue share in 2024 due to their widespread use in managing gastrointestinal disorders, enhancing immune health, and restoring gut microbiota balance.
• Based on application, the digestive and gastrointestinal disorders held the largest revenue share in 2024 due to high global prevalence of conditions such as irritable bowel syndrome, inflammatory bowel disease, Clostridioides difficile infection, and antibiotic-associated diarrhea.
• In terms of manufacturing, the clostridium difficile infection segment dominated the revenue share in 2024 due to high recurrence rates, growing antibiotic resistance, and the urgent need for effective alternatives to conventional antimicrobial therapies.
• North America human microbiome therapeutics market accounted for 48.15% of global revenue share in 2024. This dominance is attributed to the rising incidences of chronic diseases such as obesity, diabetes, and inflammatory bowel disease (IBD).
• The industry in Asia Pacific is projected to grow at the fastest pace in the coming years, owing to increasing healthcare awareness and rising disposable incomes.
• A few key players in the global human microbiome therapeutics market include Enterome SA, Ferring Pharmaceuticals, Finch Therapeutics Group Inc., Locus Biosciences Inc., MaaT Pharma, Microbiotica Ltd, Osel Inc., Seres Therapeutics Inc., Synlogic Inc., and Vedanta Biosciences.

Polaris Market Research has segmented the global human microbiome therapeutics market report on the basis of product, therapeutic area, indication, approach, and region:

By Product Outlook (Revenue, USD Billion, 2020–2034)

• Probiotics
• Prebiotics
• Medical Foods
• Prescription Drugs

By Therapeutic Area Outlook (Revenue, USD Billion, 2020–2034)

• Autoimmune Disorders
• Dental Disorders
• Digestive and Gastrointestinal Disorders
• Dermatological Disorders
• Infectious Disease
• Metabolic Disorders
• Oncology
• Others

By Indication Outlook (Revenue, USD Billion, 2020–2034)

• Acne Vulgaris
• Atopic Dermatitis
• Clostridium difficile Infection
• Colorectal Cancer
• Diabetes
• Inflammatory Bowel Disease (IBD)
• Lactose Intolerance
• Lung Cancer
• Non-alcoholic steatohepatitis (NASH)
• Obesity
• Coeliac Disease

By Approach Outlook (Revenue, USD Billion, 2020–2034)

• Small Molecule Therapies
• Single Strain Whole Bacteria
• Microbial Consortia
• Genetically Modified Single Strain Bacteria
• Phage Cocktail
• Microbial Ecosystems

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America